Praxis Precision Medicines (PRAX)
(Real Time Quote from BATS)
$41.09 USD
-2.74 (-6.25%)
Updated Jun 7, 2024 03:18 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRAX 41.09 -2.74(-6.25%)
Will PRAX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRAX
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Other News for PRAX
Praxis Precision Medicines Shapes Future with Key Elections and Approvals
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Health Care Stocks Whale Activity In Today's Session
Praxis Precision Medicines (NASDAQ:PRAX): A Wild Rollercoaster Ride
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Corbus Pharmaceuticals (CRBP)